{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:09:02Z","timestamp":1775714942828,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FISPI17\/01962"],"award-info":[{"award-number":["FISPI17\/01962"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0017\/003"],"award-info":[{"award-number":["RD16\/0017\/003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0017\/0010"],"award-info":[{"award-number":["RD16\/0017\/0010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR16\/00020"],"award-info":[{"award-number":["JR16\/00020"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013268","name":"Directorate-General for Justice and Consumers","doi-asserted-by":"publisher","award":["HOME\/2014\/JDRU\/AG\/DRUG\/7082"],"award-info":[{"award-number":["HOME\/2014\/JDRU\/AG\/DRUG\/7082"]}],"id":[{"id":"10.13039\/100013268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00233","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T04:57:23Z","timestamp":1584507443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Acute Effects of 2C-E in Humans: An Observational Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Esther","family":"Papaseit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eulalia","family":"Olesti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"P\u00e9rez-Ma\u00f1\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Torrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Grifell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar J.","family":"Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"de Sousa Fernandes Perna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes G.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mag\u00ed","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/7854_2016_54","article-title":"Predicting the abuse liability of entactogen-class, new and emerging psychoactive substances via preclinical models of drug self-administration.","volume":"32","author":"Aarde","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/hup.2545","article-title":"Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.","volume":"31","author":"Bouso","year":"2016","journal-title":"Hum. Psychopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.drugalcdep.2011.11.020","article-title":"Emerging psychoactive substance use among regular ecstasy users in Australia.","volume":"124","author":"Bruno","year":"2012","journal-title":"Drug Alcohol. Depend."},{"key":"B4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200008000-00010","article-title":"). Human pharmacology of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): psychomotor performance and subjective effects.","volume":"20","author":"Cami","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0269881111431752","article-title":"4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects.","volume":"26","author":"Caudevilla-G\u00e1lligo","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s13181-013-0295-x","article-title":"2C or not 2C: phenethylamine designer drug review.","volume":"9","author":"Dean","year":"2013","journal-title":"J. Med. Toxicol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","article-title":"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects.","volume":"56","author":"Dolder","year":"2017","journal-title":"Clin. Pharmacokinet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00213-013-3303-6","article-title":"Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.","volume":"231","author":"Eshleman","year":"2014","journal-title":"Psychopharmacology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.euroneuro.2015.05.007","article-title":"Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart.","volume":"25","author":"Farr\u00e9","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B10","year":"2018","journal-title":"Global Drug Survey [GDS]."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/643878","article-title":"Acute effects of the novel psychoactive drug 2C-B on emotions.","volume":"2015","author":"Gonz\u00e1lez","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/hup.2323","article-title":"Consumption of new psychoactive substances in a Spanish sample of research chemical users.","volume":"28","author":"Gonz\u00e1lez","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00414-018-1882-9","article-title":"Masspoisoning with NPS: 2C-E and bromo-dragon fly.","volume":"133","author":"Iwersen-Bergmann","year":"2019","journal-title":"Int. J. Legal Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.drugalcdep.2010.11.005","article-title":"Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.","volume":"115","author":"Johnson","year":"2011","journal-title":"Drug Alcohol. Depend."},{"key":"B16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0376-8716(94)90075-2","article-title":"Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI).","volume":"35","author":"Lamas","year":"1994","journal-title":"Drug Alcohol. Depend."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00131","article-title":"Soy Isoflavone extract does not increase the intoxicating effects of acute alcohol ingestion in human volunteers.","volume":"10","author":"Mart\u00ednez-Riera","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B18","first-page":"136","article-title":"Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans.","volume":"290","author":"Mas","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.drugpo.2016.11.004","article-title":"I like the old stuff better than the new stuff\u2013 Subjective experiences of new psychoactive substances.","volume":"40","author":"Matthews","year":"2016","journal-title":"Int. J. Drug Policy"},{"key":"B20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2006.11.075","article-title":"The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.","volume":"22","author":"Nagai","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics.","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"B22","year":"2017","journal-title":"Reporte de Drogas de Colombia."},{"key":"B23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ajad.12403","article-title":"Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States.","volume":"25","author":"Palamar","year":"2016","journal-title":"Am. J. Addict."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00206","article-title":"Acute pharmacological effects of 2C-B in humans: an observational study.","volume":"9","author":"Papaseit","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1038\/npp.2016.75","article-title":"Human pharmacology of mephedrone in comparison with MDMA.","volume":"41","author":"Papaseit","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics.","volume":"14","author":"Polito","year":"2019","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00455","article-title":"MDMA-Induced dissociative state not mediated by the 5-HT(2A) receptor.","volume":"8","author":"Puxty","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000077946","article-title":"Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography.","volume":"50","author":"Riba","year":"2004","journal-title":"Neuropsychobiology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s002130000606","article-title":"Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.","volume":"154","author":"Riba","year":"2001","journal-title":"Psychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (C drugs).","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"B31","first-page":"374","article-title":"Fatal toxic leukoencephalopathysecondary to overdose of a new psychoactive designer drug 2C-E (\u201dEuropa\u201d).","volume":"25","author":"Sacks","year":"2012","journal-title":"Proc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute effects of lysergic acid diethylamide in healthy subjects.","volume":"78","author":"Schmid","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119827796","article-title":"Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.","volume":"28","author":"Sexton","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"B34","author":"Shulgin","year":"1990","journal-title":"PIHKAL: A Chemical Love Story."},{"key":"B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugpo.2016.12.021","article-title":"Motivations for new psychoactive substance use among regular psychostimulant users in Australia.","volume":"43","author":"Sutherland","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.drugalcdep.2016.01.024","article-title":"New psychoactive substance use among regular psychostimulant users in Australia, 2010-2015.","volume":"161","author":"Sutherland","year":"2016","journal-title":"Drug Alcohol. Depend"},{"key":"B37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jchromb.2006.08.049","article-title":"Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry.","volume":"846","author":"Theobald","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"B38","article-title":"A case series of symptomatic patients, including one fatality, following 2C-E exposure.","volume":"49","author":"Topeff","year":"2011","journal-title":"Clin.Toxicol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6848","article-title":"Novel psychoactive substances: types, mechanisms of action, and effects.","volume":"356","author":"Tracy","year":"2017","journal-title":"BMJ"},{"key":"B40","year":"2014","journal-title":"Global Synthetic Drugs Assessment Amphetamine-type stimulants and New Psychoactive Substances."},{"key":"B41","first-page":"58","article-title":"Identification of designer drug2C-E (4-ethyl-2, 5-dimethoxy-phenethylamine) in urine following a drug overdose.","volume":"26","author":"Van Vrancken","year":"2013","journal-title":"Proc"},{"key":"B42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens.","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dial. Clin. eurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T20:43:26Z","timestamp":1614890606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":42,"alternative-id":["10.3389\/fphar.2020.00233"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00233","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]},"article-number":"233"}}